BioSpace News Archive

BioSyent Inc. announces that its Board of Directors has approved a grant of 67,252 Restricted Share Units “RSUs” to certain directors, officers, management, and employees of the Company pursuant to the Company’s Restricted Share Unit Plan.

BD, a leading global medical technology company, has expanded a voluntary recall that was initiated on June 23, 2020 for specified catalog numbers of the ChloraPrep™ 3 mL applicator due to possible fungal contamination under certain environmental conditions.

Transplant diagnostics is a medical sector that has grown at a rapid pace in the last few years as a result of the rising use of transplant operations for a variety of body parts.

Tornos Continues to Lead Global Businesses and Americas; Will Now Also Oversee Europe, Middle East and Africa (EMEA) Region Company Also Announces Planned Departure of EMEA President Didier Deltort for New Professional Appointment

Data presented at International Stroke Conference 2021 demonstrate reduced door-in door-out times, improved door-in-to-puncture times and higher rates of good reperfusion

X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced that it has agreed to sell an aggregate of 6,321,837 shares of its common stock, including pre-funded warrants to purchase common stock,

Centene Corporation (NYSE: CNC) today issued a reminder that it will release its 2021 first quarter financial results at approximately 6 a.m. (Eastern Time) on Tuesday , April 27, 2021, and host a conference call afterwards at approximately 8:30 a.m. (Eastern Time) to review the results.

Harmony Biosciences Holdings, Inc. (“Harmony”) (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs, today announced publication of a white paper sharing outcomes from a Summit on Sleep Disruption the company hosted in December 2020.

Clovis Oncology, Inc. (NASDAQ: CLVS) announced that the first presentation of data from the randomized, Phase 3 ARIEL4 study of Rubraca® (rucaparib) will take place today in an oral presentation at the Society of Gynecologic Oncology Virtual Annual Meeting on Women’s Cancer (SGO).

Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty infusion solutions that help improve quality of life for patients, today announced that Linda Tharby has been appointed President and Chief Executive Officer and will succeed Interim CEO Jim Beck effective April 12, 2021